Novo Nordisk faces US Senate committee
Novo Nordisk's CEO said the complexities of the U.S. healtchare system prevented access to $1,349 Wegovy.
Hi, it’s Bob in New York. I’ve been writing about drug costs for years, and Ozempic and Wegovy turn out to be in a unique ...
Novo Nordisk's blockbuster diabetes drug Ozempic will be eligible for U.S. government's price negotiations in less than a ...
The CEO of Novo Nordisk is set to face pointed questions on Capitol Hill Tuesday about the prices of the Danish ...
Ozempic and Wegovy are making so much money for Novo Nordisk A/S that their cumulative sales will soon surpass the ...
In a high-profile showdown Tuesday with Sen. Bernie Sanders’ Senate health committee, Novo Nordisk CEO Lars Fruergaard ...
Danish drugmaker Novo Nordisk expects its diabetes drug Ozempic will "very likely" be on the U.S. government's 2027 list of ...